^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sigvotatug vedotin (PF-08046047)

    i
    Other names: PF-08046047, SGN-B6A, SGNB6A, SGN B6A, PF08046047, PF 08046047
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, Integrin beta-6-targeted antibody-drug conjugate
    Related drugs:
    9d
    Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going? (PubMed, Cancer)
    Late-phase ADCs include trastuzumab deruxtecan (targeting HER2 [human epidermal growth factor receptor 2]), datopotamab deruxtecan and sacituzumab govitecan (targeting TROP2 [trophoblast cell-surface antigen 2]), patritumab deruxtecan (targeting HER3), telisotuzumab vedotin (targeting c-MET [cellular-mesenchymal epithelial transition factor]), and sigvotatug vedotin (targeting IB6 [integrin beta-6]). Ongoing, biomarker-driven trials and combination strategies with immunotherapy or tyrosine kinase inhibitors hold the potential to further enhance the efficacy of ADCs. In this review, the authors highlight the current landscape and future directions of ADCs in NSCLC, emphasizing available results for compounds in late-stage clinical development and different disease settings.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • patritumab deruxtecan (U3-1402) • Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Emrelis (telisotuzumab vedotin-tllv) • sigvotatug vedotin (PF-08046047)
    1m
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    2ms
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer | N=53 --> 162
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    2ms
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Pfizer
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    2ms
    C6461020: A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (2025-523526-40-00)
    P1/2, N=43, Not yet recruiting, Pfizer Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    3ms
    C6461020: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    6ms
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    sigvotatug vedotin (PF-08046047)
    6ms
    Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. (PubMed, Future Oncol)
    Approximately 714 patients will be randomized 1:1. The dual primary endpoints are progression-free survival as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; secondary endpoints include additional efficacy, safety and tolerability, pharmacokinetics, and immunogenicity endpoints.Clinical trial registration: NCT06758401 (https://clinicaltrials.gov/study/NCT06758401).
    P3 data • Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    7ms
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, Pfizer
    New P1/2 trial
    |
    sigvotatug vedotin (PF-08046047)
    9ms
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    sigvotatug vedotin (PF-08046047)
    10ms
    Be6A Lung-01: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | N=470 --> 703
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    11ms
    SGNB6A-001: A Study of Sigvotatug Vedotin in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1006, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2028 --> Mar 2029 | Trial primary completion date: Aug 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)